Syndax Pharmaceutica
SNDX
Delayed Nasdaq - 08/17 10:00:00 pm
7.18USD
-1.24%
Income Statement Evolution
Annual Income Statement Data
Actuals in M $ Estimates in M $
Fiscal Period December 20172018
Sales2,111,58
EBITDA-61,9-78,1
Operating profit (EBIT)-62,0-81,0
Pre-Tax Profit (EBT)-60,8-78,9
Net income-60,8-78,6
EPS ( $ )-2,90-3,20
Dividend per Share ( $ )--
Yield--
Announcement Date03/05/2018
09:05pm
-
Finances - Leverage
Actuals in M $ Estimates in M $
Fiscal Period December 20172018
Debt--
Finance131152
Operating income (EBITDA)-61,9-78,1
Leverage
(Debt/EBITDA)
--
Capital Expenditure0,080,25
Book Value Per Share (BVPS)4,28 $5,50 $
Cash Flow per Share--
Announcement Date03/05/2018
09:05pm
-
Balance Sheet Analysis
Financial Ratios
Size 2018e 2019e
Capitalization 168 M$ -
Entreprise Value (EV) 15,9 M$ 0,01 M$
Valuation 2018e 2019e
P/E ratio (Price / EPS)
Capitalization / Revenue 106x 13,2x
EV / Revenue 10,0x 0,00x
EV / EBITDA -0,20x -0,00x
Yield (DPS / Price) - -
Price to book (Price / BVPS) 1,31x 4,13x
Profitability 2018e 2019e
Operating Margin (EBIT / Sales) -5 121% -783%
operating Leverage (Delta EBIT / Delta Sales) -1,23x -
Net Margin (Net Profit / Revenue) -4 966% -762%
ROA (Net Profit / Asset) - -
ROE (Net Profit / Equities) -59,3% -94,6%
Rate of Dividend - -
Balance Sheet Analysis 2018e 2019e
CAPEX / CA   15,9% 2,11%
Cash Flow / Sales - -
Capital Intensity (Assets / Sales) - -
Financial Leverage (Net Debt / EBITDA) 1,94x 1,66x
Price Earning Ratio
BNA & Dividende